Skip to main content
Displaying 148 of 2853 articles.

Could future coronavirus variants fully dodge our immune system?

Studying dozens of naturally occurring and laboratory-selected mutations in SARS-CoV-2, researchers found that the virus will need to pull off a genetic feat to become fully resistant to antibodies.

Toward the first drug to treat a rare, lethal liver cancer

After scouring more than 5,000 compounds, scientists have identified several new classes of therapeutics that may help treat fibrolamellar carcinoma.

New findings to boost IVF success rates

New research casts doubt on a genetic test used to screen would-be embryos for IVF implantation. The findings suggests that these embryos can develop into healthy babies regardless of whether or not they’ve been flagged as defective by the test.

Paul Cohen, expert on fat, is promoted to associate professor

Cohen, a physician-scientist exploring obesity and metabolic disease, has conducted groundbreaking research on the complex inner workings of fat tissue.

Immunologist Daniel Mucida promoted to professor

A pioneer in the field of mucosal immunology, Mucida is unlocking the secrets of the digestive system and answering fundamental questions about the origins of human disease.

Synthetic “micro lungs” could take COVID-19 research to the next level

Scientists have developed stem-cell technology to mass-produce tissue cultures resembling our breathing organs. These tissues offer a powerful model in which to study how SARS-CoV-2 wreaks havoc in the lungs and to screen for new drugs.

As COVID-19 vaccines emerge, the search for antiviral drugs continues

Scientists are digging through drug libraries of 430,000 compounds, in pursuit of an antiviral drug that can stop the novel coronavirus in its tracks.

Scientists map the network of SARS-CoV-2’s helpers inside human cells

The virus must hijack a more than a hundred human proteins to replicate inside a cell. One of them stands out because it is an absolute requirement for infection by four different coronaviruses as well as by viruses that cause Zika, yellow fever, and other diseases.

Rockefeller issues license for the development of novel anti-inflammatory drug

The novel compound, discovered in Jan L. Breslow’s lab and now licensed to Bridge Medicines, will be designed to treat immune-mediated diseases without harming the rest of the immune system.

Rockefeller's Charles M. Rice honored with Nobel Prize for research that contributed to a cure for hepatitis C

Rice will receive the 2020 Nobel Prize in Physiology or Medicine for research that led to a cure for hepatitis C, a viral disease affecting 170 million people worldwide. His lab worked on the virus for three decades and became the first to produce a version of it that could be grown and studied i...